Peer-influenced content. Sources you trust. No registration required. This is HCN.
Practical Neurology
The TASTE-SL trial presents compelling evidence that Sanbexin, a sublingual combination of edaravone and dexborneol, offers a significant improvement in recovery for acute ischemic stroke patients, marking a notable advancement in neuroprotective treatment strategies.
Neurology March 5th 2024
MDLinx
This study underscores the critical need for precise diagnostic criteria in treating unexplained strokes and the potential reevaluation of anticoagulant use in patients with atrial cardiopathy, opening new avenues for research and patient care.
Neurology February 13th 2024
The New England Journal of Medicine
In a recent trial, late administration of tenecteplase, from 4.5 to 24 hours post-stroke onset, did not demonstrate a significant advantage over placebo in improving the functional outcomes of patients, as measured by the modified Rankin scale at 90 days.
In this pivotal trial, apixaban, when used for subclinical atrial fibrillation, demonstrated a 0.63 hazard ratio for stroke or systemic embolism compared to aspirin, indicating a significant reduction in stroke risk at the expense of increased bleeding risk.
Cardiology January 17th 2024
The study underscores the potential of dual antiplatelet therapy in reducing the risk of recurrent stroke. However, it also highlights the need for careful patient selection due to the slightly increased risk of moderate-to-severe bleeding.
Neurology January 3rd 2024
The Epoch Times
Recent studies have indicated a potential increase in stroke risk among seniors, particularly those aged 85 and older, who receive both COVID-19 and influenza vaccines simultaneously. This finding has sparked a renewed focus on the safety of administering multiple vaccines at the same time.
Geriatrics November 7th 2023